Drug trial aims to shrink rare bone tumors, spare patients from major surgery

NCT ID NCT04586660

Ongoing Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

Summary

This study is testing the drug XGEVA (denosumab) in Chinese adults and adolescents with a rare bone tumor called giant cell tumor of bone (GCTB). The main goal is to see if the drug can shrink tumors and help patients avoid major surgeries like limb amputation. Researchers will also track pain levels and side effects in about 36 participants.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Beijing Jishuitan Hospital

Beijing, Beijing Municipality, 100035, China
Harbin Meidical University Cancer Hospital

Harbin, Heilongjiang, 150000, China
National Taiwan University Hospital

Taipei, 10002, Taiwan
Peking University Peoples Hospital

Beijing, Beijing Municipality, 100044, China
Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510663, China
Taipei Veterans General Hospital

Taipei, 11217, Taiwan
Tangdu Hospital of Air Force Medical University

Xi'an, Shaanxi, 710032, China
The First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, 350005, China
The Second Affiliated hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310052, China
The Third Affiliated Hospital Of Southern Medical University

Guangzhou, Guangdong, 510630, China

Conditions

Explore the condition pages connected to this study.

GIANT CELL TUMOR OF BONE